MD
Roles
Therapeutic Areas
KYORIN Pharmaceutical Pipeline
| Drug | Indication | Phase |
|---|---|---|
| KRP-116 (Dexpanthenol/Fluocinonide) | Atopic Dermatitis | Phase 3 |
| KRP-117 | Chronic Cough | Phase 2 |
| KRP-118 | Overactive Bladder (OAB) | Phase 2 |
| Fexuprazan (Fexuclue) | Erosive Esophagitis (GERD) | Filed |
| Gefapixant (Lyfnua) | Refractory or Unexplained Chronic Cough | Approved |
| Tiotropium/Olodaterol (Spiolto) | COPD | Approved |
| Tiotropium (Spiriva) | COPD / Asthma | Approved |
| Fesoterodine (Toviaz) | Overactive Bladder (OAB) | Approved |
Leadership Team at KYORIN Pharmaceutical
PA
President and Representative Director, CEO
Chief Executive Officer
SM
Senior Managing Director
Head of Research & Development
D
Director
Board Member
OD
Outside Director
Independent Board Member
SA
Standing Audit & Supervisory Board Member
Corporate Auditor